Interaction Checker

Interacciones de Pamidronato

Pamidronato (Aredia), bisfosfonato, tiene 71 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 4; moderadas: 35; leves: 1; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 31. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (4)

  • Ácido zoledrónicobisfosfonatoGrave

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (etiqueta de Pamidronato, Contraindicaciones)

  • AlendronatobisfosfonatoGrave

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (etiqueta de Pamidronato, Contraindicaciones)

  • IbandronatobisfosfonatoGrave

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (etiqueta de Pamidronato, Contraindicaciones)

  • RisedronatobisfosfonatoGrave

    Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (etiqueta de Pamidronato, Contraindicaciones)

Interacciones moderadas (35)

  • Azelastina y fluticasonaantihistamínicoModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • CalcioVitaminas y mineralesModerada

    El calcio se une a estos fármacos en el intestino y puede reducir drásticamente la cantidad que se absorbe; separe las dosis. (NIH Office of Dietary Supplements, Calcium)

  • Calcipotriolanálogo de la vitamina DModerada

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Calcitriolanálogo de la vitamina DModerada

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (etiqueta de Pamidronato, Advertencias y precauciones)

  • CapecitabinaantimetabolitoModerada

    Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (etiqueta de Capecitabina, Interacciones medicamentosas)

  • CiclesonidacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Deferasiroxsuplemento de hierroModerada

    The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (etiqueta de Deferasirox, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Doxercalciferolanálogo de la vitamina DModerada

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (etiqueta de Pamidronato, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • HierroVitaminas y mineralesModerada

    El hierro se une a estos fármacos en el intestino y reduce su absorción; separe las dosis. (NIH Office of Dietary Supplements, Iron)

  • MagnesioVitaminas y mineralesModerada

    Los suplementos y los antiácidos que contienen magnesio reducen la absorción de estos fármacos; separe las dosis al menos dos horas. (NIH Office of Dietary Supplements, Magnesium)

  • MetilprednisolonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • OxibutininaanticolinérgicoModerada

    Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. (etiqueta de Oxibutinina, Advertencias y precauciones)

  • Paricalcitolanálogo de la vitamina DModerada

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (etiqueta de Pamidronato, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • SunitinibModerada

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TriamcinolonacorticosteroideModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Vitamina DVitaminas y mineralesModerada

    • Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (etiqueta de Pamidronato, Advertencias y precauciones)

Menciones leves (1)

  • Exemestanoinhibidor de la aromatasaLeve

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etiqueta de Exemestano, Advertencias y precauciones)

Sin interacción significativa según la etiqueta (31)

  • Acetazolamidainhibidor de la anhidrasa carbónicaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Ácido etacrínicodiurético de asaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Amiloridadiurético ahorrador de potasioSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Atenolol y clortalidonabetabloqueanteSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Benazepril e hidroclorotiazidainhibidor de la ECASin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Bisoprolol e hidroclorotiazidabetabloqueanteSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Bumetanidadiurético de asaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Clorotiazidadiurético tiazídicoSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Clortalidonadiurético tiazídicoSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECASin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Eplerenonaantagonista de la aldosteronaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Espironolactonaantagonista de la aldosteronaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Fosinopril e hidroclorotiazidainhibidor de la ECASin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Furosemidadiurético de asaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Hidroclorotiazidadiurético tiazídicoSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Indapamidadiurético tiazídicoSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECASin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Metolazonadiurético tiazídicoSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Metoprolol e hidroclorotiazidabetabloqueanteSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Quinapril e hidroclorotiazidainhibidor de la ECASin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Torasemidadiurético de asaSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Triamterenodiurético ahorrador de potasioSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioSin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (etiqueta de Pamidronato, Interacciones medicamentosas)

Compruebe Pamidronato frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.